Gut microbiome alpha-diversity is not a marker of Parkinson’s disease and multiple sclerosis

Jonathan Plassais,1,2 Guillaume Gbikpi-Benissan,1 Marine Figarol,1 Filip Scheperjans,3,4 Guy Gorochov,5 Pascal Derkinderen6,7 and Alessandra C. L. Cervino1,*

The gut–brain axis may play a central role in the pathogenesis of neurological disorders. Dozens of case–control studies have been carried out to identify bacterial markers by the use of targeted metagenomics. Alterations of several taxonomic profiles have been confirmed across several populations, however, no consensus has been made regarding alpha-diversity. A recent publication has described and validated a novel method based on richness and evenness measures of the gut microbiome in order to reduce the complexity and multiplicity of alpha-diversity indices. We used these recently described richness and evenness composite measures to investigate the potential link between gut microbiome alpha-diversity and neurological disorders and to determine to what extent it could be used as a marker to diagnose neurological disorders from stool samples. We performed an exhaustive review of the literature to identify original published clinical studies including 16S rRNA gene sequencing on Parkinson’s disease, multiple Sclerosis and Alzheimer’s disease. Richness and evenness factors loadings were quantified from sequencing files in addition with the Shannon diversity index. For each disease, we performed a meta-analysis comparing the indices between patients and healthy controls. Seven studies were meta-analysed for Parkinson’s disease, corresponding to 1067 subjects (631 Parkinson’s Disease/436 healthy controls). Five studies were meta-analysed for multiple sclerosis, corresponding to 303 subjects (164 Multiple Sclerosis/139 healthy controls). For Alzheimer’s disease, the meta-analysis was not done as only two studies matched our criteria. Neither richness nor evenness was significantly altered in Parkinson’s disease and multiple sclerosis patients in comparison to healthy controls (P-value > 0.05). Shannon index was neither associated with neurological disorders (P-value > 0.05). After adjusting for age and sex, none of the alpha-diversity measures were associated with Parkinson’s Disease. This is the first report investigating systematically alpha-diversity and its potential link to neurological disorders. Our study has demonstrated that unlike in other gastro-intestinal, immune and metabolic disorders, loss of bacterial diversity is not associated with Parkinson’s disease and multiple sclerosis.
Introduction

There is mounting evidence that gut microbiota plays a central role in the development and prognosis of neurological disorders (ND).\textsuperscript{1,2} The bidirectional communication pathway between gut bacteria and the central nervous system is now referred to as the microbiota–gut–brain axis.\textsuperscript{3–5} The prototypical gut–brain disorder is Parkinson’s disease.\textsuperscript{6} Gastro-intestinal (GI) symptoms occur in almost every Parkinson’s disease patient at some point\textsuperscript{7} and autopsy studies have consistently shown that alpha-synuclein aggregates, the defining neuropathological hallmark of the disease, are found in the gut in nearly every case.\textsuperscript{8,9} For Multiple Sclerosis (MS), nearly two-thirds of patients exhibit at least one persistent GI symptom in the disease course\textsuperscript{10} and recent reports suggested that the GI tract and especially the enteric nervous system were targeted by the autoimmune process in both experimental and human MS.\textsuperscript{11,12} Regarding Alzheimer’s disease, emerging evidence also suggests the existence of GI comorbidities and a preliminary report showed the presence of histological changes in the gut of Alzheimer’s disease subjects.\textsuperscript{13}

Microbial communities that colonize our gut can be studied in a culture-independent manner by the use of new sequencing technologies, and particularly the widely used 16S rRNA gene sequencing.\textsuperscript{14,15} Numerous clinical cross-sectional observational studies have highlighted the association between ND and gut bacterial composition.\textsuperscript{16–43} All of these studies have reported shifts in abundance of bacteria by comparing gut microbiota of ND patients to gut microbiota of healthy donors.\textsuperscript{44} No meta-analysis on the gut microbiota composition in MS and Alzheimer’s disease are available.
And as far as we know, bacterial diversity has not been exhaustively investigated in ND.

Alpha-diversity (α-diversity) is a numeric value summarizing the structure ecological community, for a single metagenomic sample, with respect to its richness, evenness or both.45 Richness commonly refers to the number of unique species that are present within a sample, while evenness refers to how species are held in even abundance with each other within a sample.46 Recently, Hagerty et al. have proposed an empirically derived method for measuring α-diversity, reducing all uncorrelated indexes to simple richness and evenness factors. The use of composite measures aims at reducing measurement error and increasing reliability, and the standardization step resulted on composite scores on the same scale between studies. Hence given the contradictory and conflicting results that had been obtained on gut microbiome α-diversity in ND, we set out the current research to meta-analyse both richness and evenness composite measures for each ND.

**Materials and methods**

**Identification of original studies**

After a first review of the literature, we focussed our research of original published data on Parkinson’s Disease, Multiple Sclerosis and Alzheimer’s disease, the three most studied diseases for their association with gut microbiota. Then, we performed three distinct queries using the PubMed database: Query#1 “Parkinson*[Title/Abstract] AND (Microbio*[Title/Abstract] OR Dysbiosis*[Title/Abstract])”, Query#2 “Multiple Sclerosis [Title/Abstract] AND (Microbio*[Title/Abstract] OR Dysbiosis*[Title/Abstract])” and Query#3 “Alzheimer*[Title/Abstract] AND (Microbio*[Title/Abstract] OR Dysbiosis*[Title/Abstract])”.

After exclusion of review articles, we reviewed all titles and/or abstracts and we included publications based on the following criteria:

- Parkinson, MS or Alzheimer is the phenotype of interest
- Human case-control studies, on adults only (≥18 years)
- Analysis of gut microbiome using 16S ribosomal RNA gene sequencing on Illumina platform
- Availability of full microbiome data (fastq files)

Owing to the low number of studies available for Alzheimer’s disease, we decided to focus our analysis on Parkinson and MS only. Authors were contacted when metagenomic data were not publicly available or to have access to metadata and/or clinical data.

**Bioinformatics processing**

Fastq files from each study were downloaded from public databases (i.e. the Sequencing Read Archive database) and when datasets were not publicly available, we requested access from authors. Non-faecal samples were excluded. For each study, fastq files were processed using the QIIME2™ pipeline (version 2019.10)47 and the quality of raw sequencing reads was assessed with FastqC. Reads were quality filtered, chimera-checked and clustered in amplicon sequencing variants using Deblur. The taxonomy of representative sequences was assessed using the RDP database (version 11).48

Alpha-diversity indices were computed in the QIIME2™ pipeline. We considered the nine following indices as reported in Hagerty et al. 2020: Menhinick, Fisher alpha, Faith pd, Shannon, Lladser pe, ENSpie (equivalent to the inverse Simpson index), Strong, Heip e and Simpson evenness measure E (Simpson e). Rarefaction curves were drawn, and each diversity index was estimated by rarefying samples at 10 000 reads.

**Statistical analysis**

The statistical analysis was performed using R (version 3.6.3). R scripts were compiled using the knitr package and saved in HTML. We performed a two-step statistical analysis. Firstly, richness and evenness were estimated from each study as suggested by Hagerty et al.46 Briefly, for each original study, all α-diversity measures were loaded and then we performed an exploratory factor analysis (EFA) using the package psych (v. 1.9.12). From each EFA, we obtained richness and evenness measures, two composite measures and orthogonal to one another, resulting from the two first factors. Before performing the meta-analysis, we checked for consistency between studies (correlation between α-diversity measures, correlation of α-diversity measures with the two composite measures, orthogonality between richness and evenness).

Next, for each disease (Parkinson’s disease and MS), we performed a meta-analysis of richness and evenness. Linear regressions were fitted to estimate standardized mean differences (SMD) for each diversity measure, with or without adjustment for cofounding factors (age and sex). Then, overall estimates were estimated by doing a weighting inverse variance meta-analysis with a random model. The generic function metagen from the R package meta (version 4.12) was used. The overall estimate and its 95% confidence interval were reported, in addition to P-value calculated based on the t distribution. P-values were adjusted using Benjamini–Hochberg correction. For Parkinson’s disease studies, adjustment for confounding factors was limited to age and sex as no other clinical variable was available. For MS, clinical data were available for only one study, hence no adjustment was possible.
Data availability statement
Almost all datasets used for this manuscript (16S rRNA sequences) are publicly available, with exception for Petrov et al.,18 Chen et al.,26 and Cekanaviciute et al.25 Clinical data and metadata are not publicly available and cannot be shared for restriction with authors. An HTML file with R code will be available under request.

Results
Identification and selection of studies
On 30 June 2020, a total of 393 records were identified from PubMed for Parkinson’s Disease (Query#1), 410 records for Multiple Sclerosis (Query#2) and 432 records for Alzheimer’s Disease (Query#3) (Supplementary Tables 1–3). PRISMA flow chart was done for Parkinson’s disease (see Fig. 1) and MS (see Fig. 2). After removing review articles, we reviewed all titles and/or abstracts. Nineteen studies16–20,22,23,28,36–43,49–51 with original gut microbiome data were found for Query#1, seven studies25–27,29,30,52,53 for Query#2 and only two studies34,35 for Query#3. Sequencing metagenomic data, clinical data and metadata were not publicly available for all studies. Authors were contacted for providing raw sequencing files and/or limited clinical data from which age, gender, BMI or weight, and constipation status. Finally, we had access to metagenomic datasets for ten original articles16,18–20,23,36–40 where Parkinson’s disease was the main phenotype of interest and six original articles25–27,29,30,52 for MS. For two studies19,20 we were not able to associate sequencing files to the clinical phenotype, hence these
two studies were discarded. Moreover, clinical data (at least age and gender) were available for five Parkinson's disease studies only.\textsuperscript{16,18,23,38,40} We had no access to raw metagenomic sequencing files for Alzheimer's disease, hence we did not perform the meta-analysis for this disease.

**Sample processing**

We processed all samples with our internal bioinformatics pipeline (see Methods). We compared per-sample sequence counts between studies after quality controls (Supplementary Fig. 1). For both Parkinson's disease and MS studies, the number of sequences was highly variable within and between each study. We defined a threshold at 10,000 sequences to ensure enough accuracy of \(\alpha\)-diversity estimates and comparability between samples and studies. Four studies reached this threshold for all samples, but two studies, Heintz-Buschard et al. and Miyake et al., did not reach the threshold for any of these samples while up to 61% of samples were removed for others. Therefore, these two studies were discarded, and the meta-analysis on Parkinson’s disease studies included a total of 1067 samples (631 Parkinson’s disease and 436 HC) and the meta-analysis on MS studies included a total of 303 samples (164 MS and 139 HC).

**Richness and evenness, two factors summarizing \(\alpha\)-diversity indices**

Nine diversity indices were estimated using QIIME2. For each study, we performed an EFA to estimate richness and evenness. We first confirmed that the two first factors explained the largest amount of variance (over 88%...
### Table 1
Correlation between z-diversity measures and Richness/Evenness estimated using an Exploratory Factor Analysis on Parkinson’s disease studies

| Variables     | Aho et al. | Hill-Burns et al. | Hopfner et al. | Keshavarzian et al. | Pietrucci et al. | Wallen et al. | Average |
|---------------|------------|-------------------|----------------|---------------------|------------------|---------------|---------|
| Richness      | 1.00       | 1.00              | 1.00           | 1.00                | 1.00             | 1.00          | –0.01   |
| Evenness      | 1.00       | 1.00              | 1.00           | 1.00                | 1.00             | 1.00          | –0.01   |
| Richness      | 1.00       | 1.00              | 1.00           | 1.00                | 1.00             | 1.00          | –0.01   |
| Evenness      | 1.00       | 1.00              | 1.00           | 1.00                | 1.00             | 1.00          | –0.01   |

After adjustment for age and sex, the overall estimate was not significant for both diseases (overall estimate = 0.12 [95% CI (–0.10; 0.33)], adjusted \( P \)-value = 0.43 for Parkinson’s disease; overall estimate = 0.26 [95% CI (–0.24; 0.76)], adjusted \( P \)-value = 0.86 for MS). The highest change in richness was observed for Keshavarzian et al., confirming results reported in this publication. We also adjusted SMD estimates for age and sex, two confounding factors. This adjustment was done for Parkinson’s disease studies only, but richness was still not altered in patients in comparison with donors (overall estimate = –0.02 [95% CI (–0.21; 0.18)], adjusted \( P \)-value = 0.87, Supplementary Fig. 2A).

We performed the same analysis for evenness. Evenness was non-significantly decreased in Parkinson’s disease with an overall estimate at –0.17 [95% CI (–0.44; 0.11), adjusted \( P \)-value = 0.43], neither in MS (overall estimate = –0.10 [95% CI (–0.50; 0.30), adjusted \( P \)-value = 0.86] [see Fig. 3B for Parkinson’s disease studies, Fig. 5B for MS studies]). For Parkinson’s disease, the evenness was decreased in five studies, and increased in only two studies (Hill-Burns et al. and Wallen et al.). After adjustment for age and sex, the overall estimate...
was still not significant for Parkinson’s disease studies (overall estimate = −0.01 [95% CI (−0.26; 0.25)], adjusted P-value = 0.96, Supplementary Fig. 2B), but the number of studies included into the meta-analysis was reduced to four.

**Shannon index was not associated neither to ND**

We performed the same analysis on the Shannon index (see Fig. 3C for Parkinson’s disease studies, Fig. 5C for MS studies). The overall estimate was still not significant for both diseases (overall estimate = 0.00 [95% CI (−0.14; 0.14)], adjusted P-value = 0.99 for Parkinson’s disease, overall estimate = 0.02 [95% CI (−0.20; 0.25)], adjusted P-value = 0.86 for MS). For Parkinson’s disease studies, after adjustment for age and sex, the overall estimate was still not significant (overall estimate = −0.03 [95% CI (−0.11; 0.17)], adjusted P-value = 0.96, Supplementary Fig. 2C).

**Discussion**

Parkinson’s disease is the neurological disorder reporting the largest number of cross-sectional studies with targeted metagenomics, and results in z-diversity index were inconsistent. Shannon index was increased in Parkinson’s disease subjects in comparison with age-matched donors, but in disagreement with others. The species richness (number of species or number of OTUs) differed also significantly in various studies, and sometimes in contradiction with Shannon results. Some studies reported z-diversity using Chao1, but results were contradictory. For example, Chao1 index was increased in Parkinson’s disease subjects in comparison with age-matched donors, in disagreement with others and in contradiction with one study observed where an increase of Chao1 in the donor group was observed. The changes in z-diversity between adults with MS compared to controls were unclear. Richness was increased in primary progressive MS patients in comparison to controls, but not Chao1. Shannon index and species richness were significantly decreased in one study while only trends or non-significant results were reported on others. Regarding Alzheimer’s disease patients, two cross-sectional studies have reported alteration of z-diversity in comparison with healthy controls.

One of the main objectives of our study was to analyse measures of z-diversity from ND studies using an empirical method to make studies comparable. We applied an EFA to each study in order to reduce the complexity and multiplicity of z-diversity indices. This method, described and justified by Hagerty et al., aims at estimating two robust and reliable z-diversity composite measures, richness and evenness, to simplify statistical association tests with clinical outcome and comparison between studies. Our results have revealed that the EFA is a powerful method for estimating richness and evenness by catching a large proportion of the variance into the two first factor loadings. We applied EFA independently to the six Parkinson’s disease studies and five MS studies, and we observed a strong consistency between all studies, meaning the correlation structure between z-diversity indices and the two composite factors was reproducible. Menhinick, Faith pd, Fisher alpha and Lladser pe indices were all associated to richness, Simpson e, Heip e, ENSpie and Strong were all associated to evenness, while Shannon index was associated to both.

The link between z-diversity measures and richness or evenness factor loadings was quite different in comparison to Hagerty et al. that reports Shannon and ENSpie both being associated to richness, while Lladser pe was associated to evenness. ENSpie, equivalent to the inverse Simpson index, can be interpreted as the number of equally abundant species in a sample, as such, it is a combination of richness and evenness. In our study, ENSpie was more related to the evenness, however, we
also observed a weak association with the richness (correlation of 0.44) despite the orthogonality between factor loadings. Hagerty et al. associated Shannon to richness, but like ENSpie, and because Shannon directly depends on the number of species and their proportion, we think that we should not reduce both Shannon index and ENSpie to only one category, and their association with one or the other will strongly depend on the data and on the number of entities used for calculations. For Lladserpe, the difference in categorization can be explained by first the lower proportion of variance explained by both factors regarding this index but also by the nature of this index, measuring how much of the sample contains unsampled species.

By nature and operational construction, richness and evenness are orthogonal meaning that they vary independently of each other. This is a key point because lot of studies reduce the analysis of alpha-diversity to the richness only, for example by reporting the number of observed OTUs. But evenness might be systematically reported for its complementarity to richness even if they are both related to the same species. We can easily imagine a simple case where two species disappear in a community A of hundreds of species and two new species appear in a community B, in conjunction with a strong disruption in abundances in only one of the two communities (for example, a blooming of some species). In that case, the richness will remain unchanged, while the

Figure 3 Richness, evenness and Shannon index meta-analyses for Parkinson’s disease studies. (A) Forest plot for the richness. (B) Forest plot for the evenness. (C) Forest plot for the Shannon index.
Figure 4 (A) Distribution of richness values for each study, stratified by disease groups (Parkinson's disease vs HC). (B) Distribution of evenness values for each study, stratified by disease groups (Parkinson's disease vs HC) (C) Distribution of Shannon values for each study, stratified by disease groups (Parkinson's disease vs HC).
evenness will be altered. Similarly in Parkinson’s disease, the meta-analysis revealed a small alteration of evenness while the richness was unchanged, this reflects changes in the abundance of some specific taxa.

Alpha-diversity is the most validated metagenomic marker of GI health and metabolic disorders. The loss of diversity, mainly measured with $\alpha$-diversity indices, has been linked to severity of a multitude of diseases, such as Inflammatory Bowel Disease, obesity and metabolic syndromes or HIV. There is not yet a gold standard regarding $\alpha$-diversity measures, even if the number of species (or Operational Taxonomic Units) and the Shannon diversity index are the two most widespread indices reported in the literature for ND studies. We evaluated whether richness, Shannon index and evenness were suitable markers of ND by performing an exhaustive re-analysis of published metagenomic datasets. Our aim was to evaluate the potential of these makers as diagnostic markers of ND. Richness and the Shannon index were associated neither with Parkinson’s disease, nor with MS. Evenness was not associated with MS, however, the meta-analysis revealed a trend for decreased evenness in Parkinson’s disease where the adjusted $P$-value was not significant but the 95% CI of the overall estimate did not include the zero value. This result should be interpreted with caution.

Our study has some limitations. First, the sample size of each study did not exceed 100 samples per group, with an exception for Parkinson’s disease studies with the inclusion a large cohort from Wallen et al. In biomarker research studies based on metagenomic datasets, it is advised to include more than 100 samples per group to increase power and to deal with inter-sample variability, which is stronger in metagenomics in comparison with other omics data. Secondly, our meta-analysis included various populations in Europe, USA and Japan. Various studies from Chinese patients have been published in Parkinson’s disease, but without access to the data we cannot conclude on $\alpha$-diversity alteration for this population. Another limitation was the lack of clinical data, and therefore the impossibility to take into account potential confounding factors. It is well-known that age, BMI,
constipation and COMT treatment are the main confounding factors reported in the literature for their association with gut microbiota.\textsuperscript{2,38} For Parkinson’s disease, we have obtained some individual clinical data, mainly age and sex, that we adjusted standardized mean difference estimates for. Results for evenness, after adjusting, were
still not significant, but the number of studies was reduced to four. Another limitation was the characterization of individual phenotypes and the absence of stratification regarding disease progression in the meta-analysis. This meta-analysis did not filter studies based on inclusion and exclusion criteria of each study; however, we know these clinical criteria can be strongly different from one study to another, and may affect consistency of findings when no adjustment for confounding factors can be done.

In QIIME 2, one of the most popular pipelines for processing 16S rRNA sequencing files, no less than thirty-one diversity metrics are available. Selecting the most useful indices can be challenging. Many of these metrics are highly correlated like Chao1 and the number of OTUs, and wrong selection of indices to analyse can lead to misinterpretation and/or multiplicity issues with statistical tests. If some \( \alpha \)-diversity indices are comprehensible and easy to interpret, like the number of species, others can be elaborate like Faith’s pd index which uses a phylogenetic tree. Then, \( \alpha \)-diversity metrics are not directly comparable between independent studies, due to variability in sample processing (targeted region, DNA extraction kit, PCR amplification, sequencing device) and diverse bioinformatics pipelines. Even the same metric, such as Shannon diversity, can result in different values due to the bioinformatics packages implementing different log scales in the algorithm. The method proposed by Hagerty and colleagues facilitates both the analysis and the interpretation, but we also demonstrated that composite measures derived from this method are suitable for meta-analysis.

Today, loss of \( \alpha \)-diversity is considered by many experts in the field as a major societal concern to the industrialized world and a potential cause for the increase in common diseases, such as inflammatory bowel disease, allergies, cancers, autism and metabolic syndrome. However, for it to be a useful clinical marker of human health, it is important to document specifically which diseases it is associated with and to what extent rebalancing the gut microbiome can be an effective public health prevention strategy in industrialized countries.

Decrease of \( \alpha \)-diversity, and in particular the Shannon index, has been repeatedly reported to be associated to various diseases, and is therefore an important clinical marker of gut health. The diagnostic of loss of diversity can help to identify unhealthy subjects, but our results suggest that these diagnostic tests will not be suitable for Parkinson’s disease and MS if they limit their interpretation of gut microbiota to only \( \alpha \)-diversity. We hypothesize that the ND gut microbiome has a more subtle dysbiosis than in GI diseases such as inflammatory bowel disease or metabolic disorders such as obesity and diabetes where observed differences in \( \alpha \)-diversity are striking. It is likely that an increase/decrease in only a limited number of bacteria are involved in the disease aetiology.

Our study was limited to \( \alpha \)-diversity measures available using the QIIME2 pipeline. However, other \( \alpha \)-diversity indices were developed to account for the lack of variance estimates and lack of unobserved species in their estimation. It would be suitable to democratize the access to these \( \alpha \)-diversity indices like the Chao-Bunge and breakaway throughout a unique platform and to go beyond the simple richness and evenness measures. Another initiative would to extend analysis of diversity analysis to functional diversity, and more precisely to functional divergence indicating a high degree of niche differentiation and analysis of diversification.

Supplementary material
Supplementary material is available at Brain Communications online.

Acknowledgements
We thank Dr Petrov from Siberian State Medical University, Tomsk, for sharing with us their raw sequencing files and some additional metadata. We thank Dr Keshavarzian from Rush Medical College, Chicago, and Dr Green from University of Illinois, Chicago for providing additional metadata and for their help in processing the sequencing files. We also thank Dr Mangalam from University of Iowa, Iowa City, and Dr Baranzini from University of California, San Francisco, for sharing raw sequencing files.

Funding
This study was funded and supported by Luxia Scientific (La Rochette, France).

Competing interests
J.P. is employed by Luxia Scientific; G.G.-B. is employed by Luxia Scientific; M.F. is employed by Luxia Scientific; G.G. is a Scientific Advisory Board member of Luxia Scientific; G.G. is an Editorial Board member of Pharmacology; G.G. has received research support from Fondation ARSEP France; P.D. is a Scientific Advisory Board member of Luxia Scientific; P.D. is an Associate Editor of Frontiers in neurodegeneration; P.D. has received research support from France Parkinson and Institut de France; F.S. is a Scientific Advisory Board member of Axial Biotherapeutics and LivaNova; F.S. has received funding for travel or speaker honoraria from Abbvie, Merck and Orion; F.S. has stock/stock options or has received Board of Directors Compensation from NeuroInnovation Oy and NeuroBiome Ltd; F.S. has received research support from Renishaw, Orion, Academy of Finland, The European Commission and Hospital District of Helsinki and Uusimaa; A.C. is employed by Luxia Scientific.
References

1. Grochowska M, Laskus T, Radkowski M. Gut microbiota in neurological disorders. Arch Immunol Ther Exp (Warsz). 2019;67(6):375–383.
2. Cryan JF, O’Riordan KJ, Sandhu K, Peterson V, Dinan TG. The gut microbiome in neurological disorders. Lancet Neurol. 2020;19(2):179–194.
3. Scheperjans F, Derkinderen P, Borghammer P. The gut and Parkinson’s disease. Nat Rev Gastroenterol Hepatol. 2009;6(5):306–314.
4. Mayer EA. Gut feelings: The emerging biology of gut-brain communication. Nat Rev Neurosci. 2011;12(8):453–466.
5. Collins SM, Surette M, Bercik P. The interplay between the intestinal microbiota and the brain. Nat Rev Microbiol. 2012;10(11):735–742.
6. Schepers J, Derkinderen P, Borghammer P. The gut and Parkinson’s disease: Hype or hope? J Parkinsons Dis. 2018;8(1):331–339.
7. Edwards LL, Quigley EMM, Pfeiffer RF. Gastrointestinal dysfunction in Parkinson’s disease: Frequency and pathophysiology. Neurology. 1992;42(4):726–732.
8. Beach TG, Adler CH, Sue LI, et al. Multi-organ distribution of phosphorylated α-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol. 2010;119(6):689–702.
9. Gelpi E, Navarro-Ortano J, Toloza E, et al. Multiple organ involvement by alpha-synuclein pathology in Lewy body disorders. Mov Disord. 2014;29(8):1010–1018.
10. Levinthai DJ, Rahman A, Nusrat S, O’Leary M, Heyman R, Bielefeldt K. Adding to the burden: Gastrointestinal symptoms and syndromes in multiple sclerosis. Mult Scler Int. 2013;2013:1–9.
11. Spear ET, Holt EA, Joyce EJ, et al. Altered gastrointestinal motility involving autoantibodies in the experimental autoimmune encephalomyelitis model of multiple sclerosis. Neurogastroenterol Motil. 2018;30(9):e13349.
12. Wunsch M, Jabari S, Voussen B, et al. The enteric nervous system is a potential autoimmunotarget in multiple sclerosis. Acta Neuropathol. 2017;134(2):281–295.
13. Puig KL, Luzt BM, Urquhart SA, et al. Overexpression of mutant amyloid-β protein precursor and presenilin 1 modulates enteric nervous system pathology. J Alzheimer’s Dis. 2015;44(4):1263–1278.doi:10.3233/JAD-142259.
14. Tringe SG, Rubin EM. Metagenomics: DNA sequencing of environmental samples. Nat Rev Genet. 2005;6(11):805–814.
15. Lynch SV, Pedersen O. The human intestinal microbiome in health and disease. N Engl J Med. 2016;375(24):2369–2379.
16. Aho VTE, Pereira PAB, Voutilainen S, et al. Gut microbiota in Parkinson’s disease: Temporal stability and relations to disease progression. EBioMedicine. 2019;44:691–707.
17. Baldini F, Hertel J, Sandt E, et al. Parkinson’s disease-associated alterations of the gut microbiome predict disease-related changes in metabolic functions. BMC Biol. 2020;18(1):1.
18. Petrov VA, Saltykova IV, Zhukova IA, et al. Analysis of gut microbiome in Parkinson’s disease. Bull Exp Biol Med. 2017;162(6):734–737.
19. Qian Y, Yang X, Xu S, et al. Alteration of the fecal microbiota in Parkinson’s disease. Brain Behav Immun. 2018;70:194–202.
20. Ren T, Gao Y, Qiu Y, et al. Gut microbiota altered in mild cognitive impairment compared with normal cognition in sporadic Parkinson’s disease. Front Neurol. 2020;11:137.
21. Schepers J, Aho V, Pereira PAB, et al. Gut microbiota are related to Parkinson’s disease and clinical phenotype. Mov Disord. 2015;30(3):350–358.
22. Vidal-Martinez G, Chin B, Camarillo C, et al. A pilot microbiota study in Parkinson’s disease patients versus control subjects, and effects of FTY720 and FTY720-mitoxy therapies in parkinsonian and multiple system atrophy mouse models. J Parkinsons Dis. 2020;10(1):185–192.
23. Wallen ZD, Appah M, Dean MN, et al. Characterizing dysbiosis of gut microbiome in PD: Evidence for overabundance of opportunistic pathogens. NPJ Parkinsons Dis. 2020;6(1):1–12.
24. Berer K, Gerdes LA, Cekanaviciute E, et al. Gut microbiota from multiple sclerosis patients enables spontaneous autoimmune encephalomyelitis in mice. Proc Natl Acad Sci U S A. 2017;114(40):10719–10724.
25. Cekanaviciute E, Yoo BB, Runia TF, et al. Erratum: Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models. Proc Natl Acad Sci U S A. 2017;114(42):E8943.
26. Chen J, Chia N, Kalari KR, et al. Multiple sclerosis patients have a distinct gut microbiota compared to healthy controls. Sci Rep. 2016;6:1–10.
27. Forbes JD, Chen C-Y, Knox NC, et al. A comparative study of the gut microbiota in immune-mediated inflammatory diseases - Does a common dysbiosis exist? Microbiome. 2018;6(1):1–15.
28. Barichella M, Severgnini M, Cilia R, et al. Unraveling gut microbiota in Parkinson’s disease and atypical parkinsonism. Mov Disord. 2019;34(3):396–405.
29. Kozhieva M, Naumova N, Alkina T, Boyko A, Vlassov V, Kabilov MR. Primary progressive multiple sclerosis in a Russian cohort: Relationship with gut bacterial diversity. BMC Microbiol. 2019;19(1):1–9.
30. Miyake S, Kim S, Suda W, et al. Dysbiosis in the gut microbiota of patients with multiple sclerosis, with a striking depletion of species belonging to clostridia XIVa and IV clusters. PLoS One. 2015;10(9):e0137429.
31. Tremlett H, Fadrosw DW, Faruqi AA, et al. Associations between the gut microbiota and host immune markers in pediatric multiple sclerosis and controls. BMC Neuro. 2016;16(1):182.
32. Cattaneo A, Cattane N, Galluzzi S, et al. Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly. Neurobiol Aging. 2017;49:60–68.
33. Manderino L, Carroll I, Azcarrate-Peril MA, et al. Preliminary evidence for an association between the composition of the gut microbiome and cognitive function in neurologically healthy older adults. J Int Neuropsychol Soc. 2017;23(8):700–705.
34. Vogt NM, Kerby RL, Dill-McFarland KA, et al. Gut microbiome alterations in Alzheimer’s disease. Sci Rep. 2017;7(1):1–11.
35. Zhuang ZQ, Shen LL, Li WW, et al. Gut microbiota is altered in patients with Alzheimer’s disease. J Alzheimer’s Dis. 2018;63(4):1337–1346.
36. Pietrucci D, Cerroni R, Unida V, et al. Dysbiosis of gut microbiota in a selected population of Parkinson’s patients. Park Relat Disord. 2019;65(June):124–130.
37. Heintz-Buschatz A, Pandey U, Wicke T, et al. The nasal and gut microbiome in Parkinson’s disease and idiopathic rapid eye movement sleep behavior disorder. Mov Disord. 2018;33(1):88–98.
38. Hill-Burns EM, Debelius JW, Morton JT, et al. Parkinson’s disease and Parkinson’s disease medications have distinct signatures of the gut microbiome. Mov Disord. 2017;32(5):739–749.
39. Hopfner F, Künstner A, Müller SH, et al. Gut microbiota in Parkinson disease in a northern German cohort. Brain Res. 2017;1667:41–45.
40. Keshavarzian A, Green SJ, Eugen PA, et al. Colonic bacterial composition in Parkinson’s disease. Mov Disord. 2015;30(10):1351–1360.
41. Li C, Cai L, Yang Y, et al. Gut microbiota differs between Parkinson’s disease patients and healthy controls in northeast China. Front Mol Neurosci. 2019;12(July):1–13.
42. Li F, Wang P, Chen Z, Xue X, Xie X, Zhang J. Alteration of the fecal microbiota in North-Eastern Han Chinese population with sporadic Parkinson’s disease. Neurosci Lett. 2019;707:134297.
43. Lin C-H, Chen C-C, Chiang H-L, et al. Altered gut microbiota and inflammatory cytokine responses in patients with Parkinson’s disease. J Neuroinflammation. 2019;16(1):129.
44. Nishiwaki H, Itô M, Ishida T, et al. Meta-analysis of gut dysbiosis in Parkinson’s disease. Mov Disord. 2020;35(9):1626–1635.
45. Willis AD. Rarefaction, alpha diversity, and statistics. Front Microbiol. 2019;10(Oct):2407.
46. Hagerty SL, Hutchison KE, Lowry CA, Bryan AD. An empirically derived method for measuring human gut microbiome alpha diversity: Demonstrated utility in predicting health-related outcomes among a human clinical sample. PLoS One. 2020;15(3):e0229204.
47. Bolyen E, Rideout JR, Dillon MR, et al. Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2. Nat Biotechnol. 2019;37(8):852–857.
48. Cole JR, Wang Q, Fish JA, et al. Ribosomal Database Project: Data and tools for high throughput rRNA analysis. Nucleic Acids Res. 2014;42(D1):633–642.
49. Li W, Wu X, Hu X, et al. Structural changes of gut microbiota in Parkinson’s disease and its correlation with clinical features. Sci China Life Sci. 2017;60(11):1223–1233.
50. Lin A, Zheng W, He Y, et al. Gut microbiota in patients with Parkinson’s disease in southern China. Park Relat Disord. 2018;53(April):82–88.
51. Hegelmaier T, Lebbing M, Duscha A, et al. Interventional influence of the intestinal microbiome through dietary intervention and bowel cleansing might improve motor symptoms in Parkinson’s disease. Cells. 2020;9(2):376.
52. Jangi S, Gandhi R, Cox LM, et al. Alterations of the human gut microbiome in multiple sclerosis. Nat Commun. 2016;7(May):12015
53. Reyners T, Devolder L, Valles-Colomer M, et al. Gut microbiome variation is associated to Multiple Sclerosis phenotypic subtypes. Ann Clin Transl Neurol. 2020;7(4):406–419.
54. Boertien JM, Pereira PAB, Aho VTE, Schepersjans F. Increasing comparability and utility of gut microbiome studies in Parkinson’s disease: A systematic review. J Parkinsons Dis. 2019;9(s2):S297–S312.
55. Gupta VK, Kim M, Bakshi U, et al. A predictive index for health status using species-level gut microbiome profiling. Nat Commun. 2020;11(1):4635.
56. Opstelten JL, Plassais J, Van Mil SWC, et al. Gut microbial diversity is reduced in smokers with Crohn’s disease. Inflamm Bowel Dis. 2016;22(9):2070–2077.
57. Le Chatelier E, Nielsen T, Qin J, et al. Richness of human gut microbiome correlates with metabolic markers. Nature. 2013;500(7464):541–546.
58. Dao MC, Clément K. Gut microbiota and obesity: Concepts relevant to clinical care. Eur J Intern Med. 2018;48(October):18–24.
59. Tuddenham SA, Koay WLA, Zhao N, et al. The impact of human immunodeficiency virus infection on gut microbiota α-diversity: An individual-level meta-analysis. Clin Infect Dis. 2020;70(4):615–627.
60. Mason NWH, Mouillot D, Lee WG, Wilson JB. Functional richness, functional evenness and functional divergence: The primary components of functional diversity. Oikos. 2005;111(1):112–118.
61. Madi N, Vos M, Legendre P, Shapiro BJ. Diversity begets diversity in microbiomes. bioRxiv. 2019;612739.